Overview
Legal name
BIOSYSTEMS TECHNOLOGY LIMITED
Region
South West England
Registered address
Unknown
Insolvency history
No
Company
Active
LTD
Company profile
Biosystems Technology Limited
Keluaran SGP: Togel Singapore | Data SGP Prize | Pengeluaran SGP Hari Ini
Keluaran sgp hari ini dan pengeluaran sgp tercepat menyajikan nomor togel singapore pools lengkap yang dirangkum ke tabel data sgp prize.
CRN
09683089
Founded
2015
Age
8
Company events
Reference milestones and recent Companies House filing stream events.
1 event
13 Jul
2015
Incorporated
InceptionCompany registered at Companies House
Public funding
4 awards
First funded
2017
Funded years
2017, 2018, 2020
Age at first award
2 years
Projects
2020
Feasibility Studies
Lead participant
Eurostars: Innovative Multifaceted Platform for Antimicrobials Commercialisation Transformation 2
1 Jun 2020 to 31 Mar 2021
Awarded
£74,826
Total cost £74,826
no public description
2018
EU-Funded
Lead participant
Innovative Multifaceted Platform for Antimicrobials Commercialisation Transformation 2
1 Oct 2018 to 30 Sep 2021
Awarded
£192,853
Total cost £321,422
Exeter scientists are part of an international team helping to find new antibiotic drugs to treat killer infections. The team, which has just received a grant from the Eurostars programme is working on a system to screen drugs early in their development to rule out those that won’t work – thereby cutting development time and costs. BioSystems Technology, ...
2018
Feasibility Studies
Lead participant
TruLarv – novel drug re-purposing platform
1 Sep 2018 to 31 Aug 2019
Awarded
£69,799
Total cost £99,713
"BioSystems Technology (BST) is at the forefront of development of alternative research models and is a world leader in the production of standardised insect larvae (""TruLarv"") for research. TruLarv are a non-mammalian technology that can be used to generate pre-clinical efficacy and toxicity data for chemicals, compounds and drugs prior to human trials...
2017
Feasibility Studies
Lead participant
TruLarv: innovative, non-mammalian preclinical technology platform
1 Sep 2017 to 31 Aug 2018
Awarded
£49,155
Total cost £70,221
BioSystems Technology (BST) is at the forefront of development of alternative research models and is a world leader in the production of standardised insect larvae (“TruLarv™”) for research. TruLarv™ are a non-mammalian technology that can be used to generate pre-clinical efficacy and toxicity data for chemicals, compounds and drugs prior to human trials....
Product types
EU-Funded
Feasibility Studies